The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin/Experiment 2
From BugSigDB
Reviewed Marked as Reviewed by Chloe on 2021/07/22
Subjects
- Location of subjects
- Italy
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Antimicrobial agent antibiotic,antibiotics,Antibiotika,Antibiotikum,antibiotique,antimicrobial,antimicrobial agents,microbicide,microbicides,Antimicrobial agent,antimicrobial agent
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Patients before Rifaximin treatment
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Patients 1 month after Rifaximin treatment
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients 1 month after Rifaximin treatment affected by ulcerative colitis, Chron's disease, Irritable Bowel Syndrome, diverticular disease, and liver cirrhosis with hepatic encephalopathy consecutively.
- Group 0 sample size Number of subjects in the control (unexposed) group
- 20
- Group 1 sample size Number of subjects in the case (exposed) group
- 20
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- 1 month prior to Rifaximin treatment.
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V1-V3
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Roche454
Statistical Analysis
- Statistical test
- metagenomeSeq
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- Yes
Signature 1
Reviewed Marked as Reviewed by Chloe on 2021/07/22
Source: Table 2
Description: Differential abundance analysis of bacterial genera compared by Rifaximin treatment time a versus time c.
Abundance in Group 1: increased abundance in Patients 1 month after Rifaximin treatment
| NCBI | Quality Control | Links |
|---|---|---|
| Lactobacillus |
Revision editor(s): Gina
Signature 2
Reviewed Marked as Reviewed by Chloe on 2021/07/22
Source: Table 2
Description: Differential abundance analysis of bacterial genera compared by rifaximin treatment at time a versus time c
Abundance in Group 1: decreased abundance in Patients 1 month after Rifaximin treatment
| NCBI | Quality Control | Links |
|---|---|---|
| Roseburia |
Revision editor(s): Gina
